Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Topical Analgesics TIB200, DCF100, and SPR300 in UV-Induced Pain
NCT02666846Phase 1Completed
- Sponsor
- Futura Medical plc
- Start
- Mar 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TIB200, DCF100 and SPR300 in pain (11 cohorts), sponsored by Futura Medical plc. Primary endpoints: Heat Pain Tolerance Test and Intensity of the UVB-induced Erythema. Started Mar 2015; status: completed.
02
Drugs
TIB200DCF100SPR300
03
Conditions
pain
Beyond the preview
Go deeper on NCT02666846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02666846.